Genomic and functional characterization of a mucosal symbiont involved in early-stage colorectal cancer.


Journal

Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316

Informations de publication

Date de publication:
13 10 2021
Historique:
received: 01 04 2021
revised: 13 07 2021
accepted: 24 08 2021
pubmed: 19 9 2021
medline: 10 2 2022
entrez: 18 9 2021
Statut: ppublish

Résumé

Colorectal cancer is a major health concern worldwide. Growing evidence for the role of the gut microbiota in the initiation of CRC has sparked interest in approaches that target these microorganisms. However, little is known about the composition and role of the microbiota associated with precancerous polyps. Here, we found distinct microbial signatures between patients with and without polyps and between polyp subtypes using sequencing and culturing techniques. We found a correlation between Bacteroides fragilis recovered and the level of inflammatory cytokines in the mucosa adjacent to the polyp. Additional analysis revealed that B. fragilis from patients with polyps are bft-negative, activate NF-κB through Toll-like receptor 4, induce a pro-inflammatory response, and are enriched in genes associated with LPS biosynthesis. This study provides fundamental insight into the microbial microenvironment of the pre-neoplastic polyp by highlighting strain-specific genomic and proteomic differences, as well as more broad compositional differences in the microbiome.

Identifiants

pubmed: 34536346
pii: S1931-3128(21)00389-9
doi: 10.1016/j.chom.2021.08.013
pmc: PMC8979638
mid: NIHMS1792253
pii:
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1589-1598.e6

Subventions

Organisme : NCI NIH HHS
ID : R01 CA220004
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM133420
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA152756
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare the following competing interests. R.W.D. is on the advisory board of MicrobiomX. W.M.G. is on the advisory board of Guardant Health, Freenome, SEngine, and consults for Diacarta and receives research support from Jannsen and Tempus. . C.W.K. receives research support from Freenome.

Références

Front Oncol. 2016 Apr 19;6:96
pubmed: 27148488
PLoS One. 2013 Oct 23;8(10):e78366
pubmed: 24194923
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Front Oncol. 2019 Nov 15;9:1146
pubmed: 31799175
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3627-32
pubmed: 26951680
Genome Res. 2016 Dec;26(12):1721-1729
pubmed: 27852649
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Bioinformatics. 2012 Sep 1;28(17):2270-1
pubmed: 22796955
Cell Host Microbe. 2018 Feb 14;23(2):203-214.e5
pubmed: 29398651
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502
Med Sci (Basel). 2018 Apr 13;6(2):
pubmed: 29652830
Bioinformatics. 2015 May 15;31(10):1674-6
pubmed: 25609793
Nucleic Acids Res. 2015 Jan;43(Database issue):D261-9
pubmed: 25428365
Nature. 2012 Nov 8;491(7423):254-8
pubmed: 23034650
PeerJ. 2018 Jan 25;6:e4320
pubmed: 29423345
Gastroenterology. 2012 Sep;143(3):844-857
pubmed: 22763141
N Engl J Med. 2016 Mar 17;374(11):1065-75
pubmed: 26981936
Biochem J. 2017 May 16;474(11):1823-1836
pubmed: 28512250
J Immunol Sci. 2018;2(2):13-18
pubmed: 30393787
Cell Microbiol. 2006 May;8(5):857-68
pubmed: 16611234
Br J Surg. 2004 Jul;91(7):790-800
pubmed: 15227685
Clin Microbiol Rev. 2009 Apr;22(2):349-69, Table of Contents
pubmed: 19366918
Nature. 2008 May 29;453(7195):620-5
pubmed: 18509436
Toxicon. 2001 Nov;39(11):1737-46
pubmed: 11595636
Science. 2011 May 20;332(6032):974-7
pubmed: 21512004
Gastroenterol Res Pract. 2013;2013:457901
pubmed: 23737765
PLoS One. 2013 Jun 17;8(6):e66643
pubmed: 23799126
Science. 2018 Feb 2;359(6375):592-597
pubmed: 29420293
Curr Protoc. 2021 Aug;1(8):e212
pubmed: 34370396
J Med Microbiol. 2009 Aug;58(Pt 8):1015-1022
pubmed: 19528164
J Clin Invest. 2019 Mar 11;129(4):1699-1712
pubmed: 30855275
Int J Cancer. 2011 May 1;128(9):2038-49
pubmed: 20648559
BMC Bioinformatics. 2010 Mar 08;11:119
pubmed: 20211023
Exp Mol Med. 2013 Dec 06;45:e66
pubmed: 24310172
PeerJ. 2015 Oct 08;3:e1319
pubmed: 26500826
Clin Microbiol Rev. 2007 Oct;20(4):593-621
pubmed: 17934076
Gut Microbes. 2017 Jul 4;8(4):374-383
pubmed: 28632016

Auteurs

Melissa C Kordahi (MC)

Department of Pathology, University of Washington, Seattle, WA 98195, USA; Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA.

Ian B Stanaway (IB)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA.

Marion Avril (M)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA.

Denise Chac (D)

Department of Pathology, University of Washington, Seattle, WA 98195, USA; Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA.

Marie-Pierre Blanc (MP)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA.

Benjamin Ross (B)

Department of Microbiology and Immunology at Dartmouth College, Hanover, NH 03755, USA.

Christian Diener (C)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Institute for Systems Biology, Seattle, WA 98105.

Sumita Jain (S)

Department of Periodontics, School of Dentistry, University of Washington, Seattle, WA 98195, USA.

Paul McCleary (P)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA.

Ana Parker (A)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA.

Vincent Friedman (V)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA.

Jennifer Huang (J)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Wynn Burke (W)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Sean M Gibbons (SM)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Department of Bioengineering, University of Washington, Seattle, WA 98195, USA; Institute for Systems Biology, Seattle, WA 98105.

Amy D Willis (AD)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Department of Biostatistics University of Washington, Seattle, WA 98195, USA.

Richard P Darveau (RP)

Department of Periodontics, School of Dentistry, University of Washington, Seattle, WA 98195, USA.

William M Grady (WM)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Cynthia W Ko (CW)

Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA.

R William DePaolo (RW)

Department of Pathology, University of Washington, Seattle, WA 98195, USA; Center for Microbiome Science & Therapeutics, University of Washington, Seattle, WA 98195, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: wdepaolo@medicine.washington.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH